undamentalytics Newsletter
Sign in

Dare Bioscience, Inc. balance sheet

At the end of fiscal 2025, Dare Bioscience, Inc. had total assets of $32.5m, total liabilities of $29.6m and shareholders' equity of $2.8m. It held $24.7m in cash against $0 of debt: net cash of $24.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142016Dec 20162021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents175510523510162513
Receivables———10—————
Total current assets—6530554318182717
Total assets—7530564421223222
Accounts payable—111223111
Deferred revenue (current)———3—0————
Total current liabilities—1581163220222417
Short-term debt———————0——
Total debt0901000000
Total liabilities———1173326283023
Shareholders' equity−80−9445−13911−5−63−1
Net debt (negative = net cash)−173−511−52−35−10−16−25−13
Shares outstanding——————8m9m—15m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DARE vs RNACABSI vs DAREDARE vs LGVNDARE vs OVID

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Dare Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dare Bioscience, Inc.